



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ian Churcher et al.

Serial No.: 10/679,902

Case No.: T1593

Filed: October 6, 2003

For: CYCLOHEXYL SULPHONES AS GAMMA-SECRETASE INHIBITORS

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22131-1450

SUBMITTAL OF PRIORITY DOCUMENTS

Sir:

Enclosed please find a certified copy of the following priority documents for submittal with respect to the above-noted application:

Foreign Application - Great Britain 0223038.1 filed 10/04/2002

Respectfully submitted,

By

John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: January 23, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.
By Date Jan. 23, 2004



I hereby certify that this correspondence is being
deposited with the United States Post Office at
first class mail in an envelope addressed to
Commissioner of Patents, D.O., U.S. Patent Office,
Alexandria, Virginia, 23313-1420.
Appasula Peala.

MERC & CO., Inc.

By _____ Date _____



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Stephen Hordley

Dated

25 September 2003





The
Patent
Office

1/77

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

T1593PV

2. Patent application number

(The Patent Office will fill in this part)

0223038.1

07OCT02 E753376-1 D02639

P01/7700 0.00-0223038.1

04 OCT 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Patents ADP number (if you know it)

00597799001 ✓

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Therapeutic compounds

5. Name of your agent (if you have one)

Mr. J. Horgan

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Merck & Co., Inc.
European Patent Department
Terlings Park
Eastwick Road
Harlow
Essex CM20 2QR

Patents ADP number (if you know it)

007536832001 4448791001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority Application number
(if you know it)Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	46
Claim(s)	0
Abstract	0
Drawing(s)	0

CF


-
10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

11.

I/We request the grant of a patent on the basis of this application.

Signature


Mr. J. Horgan

Date 04 October 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. J. Horgan

01279 440625

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

THERAPEUTIC COMPOUNDS

The present invention relates to a novel class of compounds, their salts, pharmaceutical compositions comprising them, processes for making them and their use in therapy of the human body. In particular, the invention relates to novel cyclohexyl sulphones which modulate the processing of APP by γ -secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.

Alzheimer's disease (AD) is the most prevalent form of dementia. Although primarily a disease of the elderly, affecting up to 10% of the population over the age of 65, AD also affects significant numbers of younger patients with a genetic predisposition. It is a neurodegenerative disorder, clinically characterized by progressive loss of memory and cognitive function, and pathologically characterized by the deposition of extracellular proteinaceous plaques in the cortical and associative brain regions of sufferers. These plaques mainly comprise fibrillar aggregates of β -amyloid peptide (A β). The role of secretases, including the putative γ -secretase, in the processing of amyloid precursor protein (APP) to form A β is well documented in the literature and is reviewed, for example, in WO 01/70677.


There are relatively few reports in the literature of compounds with inhibitory activity towards γ -secretase, as measured in cell-based assays. These are reviewed in WO 01/70677. Many of the relevant compounds are peptides or peptide derivatives.

WO 00/50391 discloses a broad class of sulphonamides as modulators of the production of β -amyloid, but neither discloses nor suggests the compounds of the present invention.

The present invention provides a novel class of cyclohexyl sulphones which are useful in the treatment or prevention of AD by modulating the processing of APP by the putative γ -secretase, thus arresting the production of A β . The compounds of the invention generally combine a

high affinity for the target enzyme with favourable pharmacokinetic properties.

According to the invention, there is provided a compound of formula I:



5

wherein n is 1 or 2;

R¹ represents CF₃ or C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₉cycloalkyl or C₃₋₆cycloalkylC₁₋₆alkyl, any of which may bear up to 2 substituents selected from halogen, CN, CF₃, OR³, COR³, CO₂R³, OCOR⁴, SO₂R⁴, N(R⁵)₂,

10 and CON(R⁵)₂,

or R¹ represents aryl, arylC₁₋₆alkyl, C-heterocyclyl or C-heterocyclylC₁₋₆alkyl;

R² represents H or C₁₋₄alkyl;

R³ represents H, C₁₋₄alkyl, phenyl or heteroaryl;

15 R⁴ represents C₁₋₄alkyl, phenyl or heteroaryl;

R⁵ represents H or C₁₋₄alkyl, or two R⁵ groups together with a nitrogen atom to which they are mutually attached complete an azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine or thiomorpholine-1,1-dioxide ring;

20 Ar¹ and Ar² independently represent phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, CHO, CH=NOH, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₂₋₆acyl, C₂₋₆alkenyl and C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy;

25 "aryl" at every occurrence thereof refers to phenyl or heteroaryl which optionally bear up to 3 substituents selected from halogen, CN, NO₂, CF₃, OCF₃, OR³, COR³, CO₂R³, OCOR⁴, N(R⁵)₂, CON(R⁵)₂ and

optionally-substituted C₁-alkyl, C₁-alkoxy, C₂-alkenyl or C₂-alkenyloxy wherein the substituent is selected from halogen, CN, CF₃, phenyl, OR³, CO₂R³, OCOR⁴, N(R⁵)₂ and CON(R⁵)₂; and

"C-heterocyclyl" and "N-heterocyclyl" at every occurrence thereof
5 refer respectively to a heterocyclic ring system bonded through carbon or nitrogen, said ring system being non-aromatic and comprising up to 10 atoms, at least one of which is O, N or S, and optionally bearing up to 3 substituents selected from oxo, halogen, CN, NO₂, CF₃, OCF₃, OR³, COR³, CO₂R³, OCOR⁴, OSO₂R⁴, N(R⁵)₂, CON(R⁵)₂ and optionally-substituted
10 phenyl, C₁-alkyl, C₁-alkoxy, C₂-alkenyl or C₂-alkenyloxy wherein the substituent is selected from halogen, CN, CF₃, OR³, CO₂R³, OCOR⁴, N(R⁵)₂ and CON(R⁵)₂;

or a pharmaceutically acceptable salt thereof.

Where a variable occurs more than once in formula I, the individual
15 occurrences are independent of each other, unless otherwise indicated.

As used herein, the expression "C_{1-x}alkyl" where x is an integer greater than 1 refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups include methyl, ethyl, n-propyl, isopropyl and
20 t-butyl. Derived expressions such as "C₂-alkenyl", "hydroxyC₁-alkyl", "heteroarylC₁-alkyl", "C₂-alkynyl" and "C₁-alkoxy" are to be construed in an analogous manner.

The expression "C₃₋₉cycloalkyl" as used herein refers to nonaromatic monocyclic or fused bicyclic hydrocarbon ring systems comprising from 3 to 25 9 ring atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl and bicyclo[2.2.1]heptyl. Monocyclic systems of 3 to 6 members are preferred.

The expression "C₃₋₆ cycloalkylC₁-alkyl" as used herein includes cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and
30 cyclohexylmethyl.

The expression "C₂-acyl" as used herein refers to C₁-alkylcarbonyl groups in which the alkyl portion may be straight chain, branched or cyclic, and may be halogenated. Examples include acetyl, propionyl and trifluoroacetyl.

5 The expression "heterocyclyl" as defined herein includes both monocyclic and fused bicyclic systems of up to 10 ring atoms selected from C, N, O and S. Mono- or bicyclic systems of up to 7 ring atoms are preferred, and monocyclic systems of 4, 5 or 6 ring atoms are most preferred. Examples of heterocyclic ring systems include azetidinyl,
10 pyrrolidinyl, 3-pyrrolinyl, terahydrofuryl, 1,3-dioxolanyl, tetrahydrothiophenyl, tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-aza-5-oxabicyclo[2.2.1]heptyl and 1,4-dioxa-8-azaspiro[4.5]decanyl. Unless otherwise indicated, heterocyclyl
15 groups may be bonded through a ring carbon atom or a ring nitrogen atom where present. "C-heterocyclyl" indicates bonding through carbon, while "N-heterocyclyl" indicates bonding through nitrogen.

The expression "heteroaryl" as used herein means a monocyclic system of 5 or 6 ring atoms, or fused bicyclic system of up to 10 ring atoms, selected from C, N, O and S, wherein at least one of the constituent rings is aromatic and comprises at least one ring atom which is other than carbon. Monocyclic systems of 5 or 6 members are preferred. Examples of heteroaryl groups include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furyl, thienyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 25 isothiazolyl, imidazolyl, oxadiazolyl, triazolyl and thiadiazolyl groups and benzo-fused analogues thereof. Further examples of heteroaryl groups include tetrazole, 1,2,4-triazine and 1,3,5-triazine. Pyridine rings may be in the N-oxide form.

Where a phenyl group or heteroaryl group bears more than one substituent, preferably not more than one of said substituents is other than halogen or alkyl. Where an alkyl group bears more than one

substituent, preferably not more than one of said substituents is other than halogen.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.

5 For use in medicine, the compounds of formula I may advantageously be in the form of pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of formula I or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, benzenesulfonic acid, methanesulfonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, 10 carbonic acid or phosphoric acid. Alternatively, where the compound of the invention carries an acidic moiety, a pharmaceutically acceptable salt may be formed by neutralisation of said acidic moiety with a suitable base. Examples of pharmaceutically acceptable salts thus formed include alkali metal salts such as sodium or potassium salts; ammonium salts; alkaline 15 earth metal salts such as calcium or magnesium salts; and salts formed with suitable organic bases, such as amine salts (including pyridinium salts) and quaternary ammonium salts.

20

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the 25 compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

In the compounds of formula I, n is 1 or 2, preferably 2.

30 R¹ is preferably CF₃, aryl or arylalkyl, or an alkyl, alkenyl, cycloalkyl or cycloalkylalkyl group, optionally substituted as described

previously. Preferred substituents include halogen (especially fluorine or chlorine), CF_3 , CN, OR³ (especially OH, OMe and OEt), COR³ (especially acetyl), CO₂R³ (especially CO₂H, CO₂Me and CO₂Et), SO₂R⁴ (especially methanesulfonyl), N(R⁵)₂ (especially when the R⁵ groups complete a ring) and CON(R⁵)₂ (especially CONH₂).

Examples of alkyl groups represented by R¹ include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, 2,2,2-trifluoroethyl, chloromethyl, 3-chloropropyl, 2-chloro-2-propyl, cyanomethyl, 2-hydroxyethyl, 2-methoxyethyl, 2-hydroxy-2-methylpropyl, carboxymethyl, methoxycarbonylmethyl, 1-carboxyethyl, 1-ethoxycarbonylethyl, carbamoylmethyl, 2-(pyrrolidin-1-yl)ethyl, 2-(morpholin-4-yl)ethyl and MeSO₂CH₂-.

Examples of alkenyl groups represented by R¹ include vinyl and allyl.

Examples of cycloalkyl and cycloalkylalkyl groups represented by R¹ include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl and cyclopentylmethyl.

When R¹ represents aryl or arylalkyl, the aryl group may be phenyl or heteroaryl (especially 5- or 6-membered heteroaryl), optionally substituted as defined previously. Preferred substituents include halogen (especially chlorine, bromine or fluorine), CN, CF₃, OCF₃, alkyl (especially methyl), OH, alkoxy (especially methoxy) and alkoxycarbonyl (such as methoxycarbonyl). Preferred heteroaryl groups include pyridine, pyrimidine, furan, thiophene, thiazole, isothiazole, isoxazole, pyrazole, imidazole, triazole, thiadiazole and tetrazole, especially pyridine, furan, thiophene, thiazole, isothiazole, isoxazole, pyrazole, imidazole, triazole, and tetrazole.

Examples of aryl groups represented by R¹ include phenyl, 2-, 3- and 4-fluorophenyl, 2,4-difluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-cyanophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, 2-methoxyphenyl, 5-chloro-2-methoxyphenyl, 2-pyridyl, 4-pyridyl, 6-chloro-3-pyridyl, 2-furyl,

2-thienyl, 3-thienyl, 2-thiazolyl, 5-isothiazolyl, 2-imidazolyl, 2-methylfuran-3-yl, 5-chloro-2-thienyl, 4-chloro-2-thienyl, 3-chloro-2-thienyl, 3-bromo-2-thienyl, 4-bromo-2-thienyl, 5-methyl-2-thienyl, 2-(methoxycarbonyl)-3-thienyl, 4-methylthiazol-3-yl, 1-methylimidazol-2-yl,
5 1-methylimidazol-5-yl, 1-methylimidazol-4-yl, 3-chloro-1,5-dimethylpyrazol-4-yl, 3,5-dimethylisoxazol-4-yl, 1-methyl-1,2,3,4-tetrazol-5-yl, 1,2,4-triazol-3-yl, 1-methyl-1,2,4-triazol-3-yl, 2-methyl-1,2,4-triazol-3-yl and 4-methyl-1,2,4-triazol-3-yl.

Arylalkyl groups represented by R¹ are typically optionally substituted benzyl, phenethyl, heteroarylmethyl or heteroarylethyl groups. Examples include benzyl, 2-furylmethyl, 2-thienylmethyl and 1-(2-thienyl)ethyl. Preferred examples include benzyl.

R² preferably represents H or methyl, most preferably H.

R³ preferably represents H, C₁₋₄alkyl, phenyl, pyridyl, or 5-membered heteroaryl. Most preferably, R³ represents H or C₁₋₄alkyl.

R⁴ preferably represents C₁₋₄alkyl, phenyl, pyridyl, or 5-membered heteroaryl. Most preferably, R³ represents C₁₋₄alkyl.


Ar¹ and Ar² independently represent optionally substituted phenyl or heteroaryl. Ar¹ is preferably selected from optionally substituted phenyl and optionally substituted 6-membered heteroaryl. Preferred 6-membered heteroaryl embodiments of Ar¹ include optionally substituted pyridyl, in particular optionally substituted 3-pyridyl. Ar¹ is preferably selected from 5-(trifluoromethyl)-3-pyridyl and phenyl which is optionally substituted in the 4-position with halogen, CN, vinyl, allyl, acetyl, methyl or mono-, di- or trifluoromethyl. In one preferred embodiment of the invention Ar¹ represents 4-chlorophenyl. In another preferred embodiment Ar¹ represents 4-trifluoromethylphenyl.

Ar² preferably represents optionally substituted phenyl, in particular phenyl bearing 2 or 3 substituents selected from halogen, CN, CF₃ and optionally-substituted alkyl. Ar² is typically selected from phenyl groups bearing halogen substituents (preferably fluorine) in the 2- and 5-

positions or in the 2-, 3- and 6-positions, or from phenyl groups bearing a fluorine substituent in the 2-position and halogen, CN, methyl or hydroxymethyl in the 5-position. In a preferred embodiment of the invention, Ar² represents 2,5-difluorophenyl.

5 In a particular embodiment, Ar¹ is 4-chlorophenyl or 4-trifluoromethylphenyl and Ar² is 2,5-difluorophenyl.

A preferred subclass of the compounds of the invention are the compounds of formula II:



II

10 wherein X represents N or CH;

R⁶ represents H, F, Cl, Br, CN, CF₃, CH=CH₂ or CH₃;

R⁷ represents F, Cl, Br, CN, CH₃ or CH₂OH; and

R¹ has the same definition and preferred identities as before; and pharmaceutically acceptable salts thereof.

15 When X represents N, R⁶ is preferably CF₃.

In a preferred embodiment, R¹ is selected from:

(a) CF₃;

(b) C₁₋₆alkyl which optionally bears up to 2 substituents selected from halogen, CN, CF₃, OR³, CO₂R³, SO₂R⁴, N(R⁵)₂, and CON(R⁵)₂; and

20 (c) phenyl, pyridyl or 5-membered heteroaryl which optionally bear up to 3 substituents selected from halogen, CN, CF₃, OR³, COR³, CO₂R³, OCOR⁴, N(R⁵)₂, CON(R⁵)₂ and optionally-substituted C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl or C₂₋₆alkenyloxy wherein the substituent is selected from halogen, CN, CF₃, phenyl, OR³, CO₂R³, OCOR⁴, N(R⁵)₂ and CON(R⁵)₂;

25 where R³, R⁴ and R⁵ have the same definitions and preferred identities as before.

R¹ very aptly represents CF₃.

Examples of individual compounds in accordance with the invention are provided in the Examples section appended hereto.

The compounds of formula I have an activity as modulators of the
5 processing of APP by γ -secretase.

The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or the pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets,
10 pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid
15 compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums or surfactants such as sorbitan monooleate, polyethylene glycol, and other pharmaceutical diluents, e.g.
20 water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the
25 composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 250 mg, for example 1, 2, 5, 10, 25, 50, 100, 200 or 250 mg, of the active ingredient.
30 The tablets or pills of the novel composition can be coated or otherwise

compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer
5 which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

10 The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for
15 aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, poly(vinylpyrrolidone) or gelatin.

The present invention also provides a compound of formula I or a
20 pharmaceutically acceptable salt thereof for use in a method of treatment of the human body. Preferably the treatment is for a condition associated with the deposition of β -amyloid. Preferably the condition is a neurological disease having associated β -amyloid deposition such as Alzheimer's disease.


25 The present invention further provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing Alzheimer's disease.

The present invention further provides a method of treatment of a subject suffering from or prone to a condition associated with the
30 deposition of β -amyloid which comprises administering to that subject an effective amount of a compound according to formula I or a

pharmaceutically acceptable salt thereof. Preferably the condition is a neurological disease having associated β -amyloid deposition such as Alzheimer's disease.

For treating or preventing Alzheimer's Disease, a suitable dosage 5 level is about 0.01 to 250 mg/Kg per day, preferably about 0.10 to 100 mg/Kg per day, especially about 1.0 to 50 mg/Kg, and for example about 10 to 30 mg/Kg of body weight per day. Thus, a dose of about 500mg per person per day may be considered. The compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, dosage 10 outside these limits may be used.


The compounds of formula I in which R² is H may be prepared by reacting a sulfonyl chloride R¹SO₂Cl with an amine of formula III:




where R¹, Ar¹ and Ar² have the same meanings as before. The reaction is 15 typically carried out at ambient or reduced temperature in the presence of a tertiary amine such as triethylamine in an aprotic solvent such as dichloromethane.

The compounds of formula I in which R² is other than H may be prepared by alkylation of the corresponding compounds of formula I in 20 which R¹ is H, e.g. by heating with the appropriate alkyl iodide in THF in the presence of sodium hydride.

The amines of formula III may be obtained by reduction of the azides IV:




where Ar¹ and Ar² have the same meanings as before. The azides IV are obtained via nucleophilic displacement of the mesylates V(a), formed from the *trans* alcohols V(b) by reaction with methanesulfonyl chloride:



V (a) R = SO₂Me
 (b) R = H

5 where Ar¹ and Ar² have the same meanings as before. The alcohols V(b) are obtained by reduction of the cyclohexanones VI:



10 where Ar¹ and Ar² have the same meanings as before. The reduction may be carried out using sodium borohydride in ethanol, with isolation of the *trans* isomer by chromatography.

Detailed procedures for these steps, and for the synthesis of cyclohexanones VI, are provided in the Examples section.

15 It will be apparent to those skilled in the art that individual compounds of formula I prepared by the above routes may be converted into other compounds in accordance with formula I by means of well known synthetic techniques such as alkylation, esterification, amide coupling, hydrolysis, oxidation and reduction. Such techniques may likewise be carried out on precursors of the compounds of formula I. For example, substituents on the aromatic groups Ar¹ or Ar² may be added or interconverted by means of standard synthetic processes carried out on the compounds of formula I or their precursors. For example, a chlorine or bromine atom on Ar¹ or Ar² may be replaced by vinyl by treatment with vinyltributyltin in the presence of tri-*t*-butylphosphine, cesium fluoride and tris(dibenzylideneacetone)dipalladium(0). Ozonolysis of the vinyl

group provides the corresponding formyl derivative, which may be transformed in a variety of ways, including oxidation to the corresponding acid, reduction to the corresponding benzyl alcohol, and conversion to the corresponding nitrile by treatment with hydroxylamine then

5 triphenylphosphine and carbon tetrachloride.

Where they are not themselves commercially available, the starting materials and reagents employed in the above-described synthetic schemes may be obtained by the application of standard techniques of organic synthesis to commercially available materials.

10 It will be appreciated that many of the above-described synthetic schemes may give rise to mixtures of stereoisomers. Such mixtures may be separated by conventional means such as fractional crystallisation and preparative chromatography.

Certain compounds according to the invention may exist as optical
15 isomers due to the presence of one or more chiral centres or because of the overall asymmetry of the molecule. Such compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard
20 techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid, followed by fractional crystallisation and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric
25 esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional
30 protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene &

P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd ed., 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

- An assay which can be used to determine the level of activity of compounds of the present invention is described in WO01/70677. A preferred assay to determine such activity is as follows:
- 1) SH-SY5Y cells stably overexpressing the β APP C-terminal fragment SPA4CT, are cultured at 50-70% confluency. 10mM sodium butyrate is added 4 hours prior to plating.
 - 2) Cells are plated in 96-well plates at 35,000 cells/well/100 μ L in Dulbecco's minimal essential medium (DMEM) (phenol red-free) + 10% foetal bovine serum (FBS), 50mM HEPES buffer (pH7.3), 1% glutamine.
 - 3) Make dilutions of the compound plate. Dilute stock solution 18.2x to 5.5% DMSO and 11x final compound concentration. Mix compounds vigorously and store at 4°C until use.
 - 4) Add 10 μ L compound/well, gently mix and leave for 18h at 37°C, 5% CO₂.
 - 5) Prepare reagents necessary to determine amyloid peptide levels, for example by Homogeneous Time Resolved Fluorescence (HTRF) assay.
 - 6) Plate 160 μ L aliquots of HTRF reagent mixture to each well of a black 96-well HTRF plate.
 - 7) Transfer 40 μ L conditioned supernatant from cell plate to HTRF plate. Mix and store at 4°C for 18 hours.
 - 8) To determine if compounds are cytotoxic following compound administration, cell viability is assessed by the use of redox dye reduction. A typical example is a combination of redox dye MTS (Promega) and the electron coupling reagent PES. This mixture is made up according to the manufacturer's instructions and left at room temperature.
 - 9) Add 10 μ L/well MTS/PES solution to the cells; mix and leave at 37°C.

10) Read plate when the absorbance values are approximately 0.4 – 0.8.
(Mix briefly before reading to disperse the reduced formazan product).

11) Quantitate amyloid beta 40 peptide using an HTRF plate reader.
Alternative assays are described in *Biochemistry*, 2000, 39(30),

5 8698-8704.

See also, *J. Neuroscience Methods*, 2000, 102, 61-68.

The Examples of the present invention all had an ED₅₀ of less than 0.5μM, in most cases less than 100nM, and in preferred cases less than 10nM, in at least one of the above assays.

10 The following examples illustrate the present invention.

EXAMPLES

Intermediate A

4-(4-chlorobenzenesulfonyl)-4-(2,5-difluorophenyl)cyclohexylamine



- 15 (1) 4-Chlorothiophenol (3.6 g, 0.025 mol) in dichloromethane (100 mL) was treated with 2,5-difluorobenzyl bromide (5.17 g, 0.025 mol) and triethylamine (3.9 ml, 0.028 mol). The reaction was stirred for 2 hours then diluted with dichloromethane (250 mL) and washed with water (100 mL) and brine (100 mL). The separated organic layer was dried (MgSO₄), 20 evaporated to dryness, and the product purified by passing down a plug of silica eluting with hexane-ethyl acetate mixtures to give 4-chlorophenyl 2,5-difluorobenzyl sulfide (5.12g). ¹H NMR CDCl₃ 7.23 (4H, s), 6.69-6.86 (3H, m) and 4.04 (2H, s).
- (2) This thioether (5.12 g, 0.018 mol) in dichloromethane (100 mL) was 25 treated with m-chloroperoxybenzoic acid (50% w/w, 14.3 g, 0.042 mol) and stirred for 2 hours. The reaction was washed with sodium sulfite (5% aqueous, 100 mL) and brine (50 mL), dried (MgSO₄) and evaporated to dryness. The sulfone product was purified by flash chromatography on

silica eluting with hexane-ethyl acetate mixtures to give the sulfone (3.6 g). ^1H NMR (CDCl_3) δ 7.61 (2H, d, J = 8.6 Hz), 7.45 (2H, d, J = 8.6 Hz), 7.13-7.08 (1H, m), 7.05-7.01 (1H, m), 6.99-6.87 (1H, m) and 4.36 (2H, s).

(3) A solution of this sulfone (1 g, 3.31 mmol) and methyl acrylate (0.84 mL, 9.27 mmol) in tetrahydrofuran (30 mL) was treated dropwise with potassium *t*butoxide (1M solution in tetrahydrofuran, 3.64 mL, 3.64 mmol). The reaction was stirred for 2 hours, diluted with ethyl acetate (100 mL) and washed with water (50 mL) and brine (50 mL). The organic phase was separated, dried (MgSO_4) and evaporated to dryness, and the product purified by flash chromatography on silica eluting with hexane-ethyl acetate mixtures to give 1.0 g 4,4-disubstituted-2-hydroxycyclohexene-1-carboxylate product. ^1H NMR (CDCl_3) δ 12.0 (1H, s), 7.41 (4H, s), 7.06-7.0 (2H, m), 6.87-6.81 (1H, s), 3.81 (3H, s), 3.38 (1H, dd, J = 3.2, 15.8 Hz), 3.02-2.92 (2H, m), 2.52 (1H, dd, J = 5.7, 18.5Hz), 2.3-2.2 (1H, m) and 2.2-2.1 (1H, m).

(4) The ester from the foregoing step (1.0 g, 2.25 mmol) in dimethylsulfoxide (10 mL) was treated with sodium chloride (0.3 g, 4.96 mmol) and water (0.9 mL, 4.96 mmol) and heated at 150°C for 2 hours. The cooled reaction mixture was diluted with ethyl acetate (100 mL), washed with saturated aqueous ammonium chloride solution (100 mL), dried (MgSO_4) and evaporated to dryness. The product was purified by flash chromatography on silica eluting with hexane-ethyl acetate mixtures to give 4-[(4-chlorophenyl)sulfonyl]-4-(2, 5-difluorophenyl)cyclohexanone (0.5 g). ^1H NMR (CDCl_3) δ 7.43-7.37 (4H, m), 7.22-7.1 (2H, m), 6.97-6.9 (1H, m), 3.05-2.98 (2H, m), 2.61-2.53 (4H, m) and 2.25-2.15 (2H, m).

(5) The cyclohexanone (0.1 g, 0.26 mmol) in methanol (2 ml) was treated with NaBH_4 (0.098 g, 0.26 mmol), stirred for 1 hour, quenched with HCl (1N, 10 ml), diluted with ethyl acetate (20 ml), then the organic phase was separated, dried (MgSO_4) and evaporated to dryness. The *trans* 4-[(4-chlorophenyl)sulfonyl]-4-(2, 5-difluorophenyl)cyclohexanol was purified on silica eluting with hexane-ethyl acetate mixtures. 0.052 g. ^1H

NMR CDCl₃ 7.39-7.33 (4H, m), 7.11-7.02 (2H, m), 6.88-6.82 (1H, m), 3.80-3.73 (1H, m), 2.80-2.60 (2H, m), 2.22-2.16 (2H, m), 2.08-2.04 (2H, m), 1.53(1H, br) and 1.27-1.13 (2H, m).

(6) To this alcohol (2.7 g, 6.9 mmol) and triethylamine (1.45 ml, 10.3 mmol) in dichloromethane (50 ml) was added methanesulfonyl chloride (0.645 ml, 8.9 mmol) at -30°C. After 30 minutes the mixture was washed with water (20 ml), 10% aqueous citric acid (20 ml) and saturated aqueous sodium hydrogen carbonate (50 ml), dried (MgSO₄) and evaporated to dryness. The solid was triturated with ether to give the mesylate (2.6 g)


10 ¹H NMR (CDCl₃) 7.40-7.37 (4H, m), 7.12-7.07 (2H, m), 6.92-6.83 (1H, m), 4.78-4.65 (1H, m), 2.96 (3H, s), 2.88-2.52 (2H, m), 2.29-2.21 (4H, m) and 1.59-1.47 (2H, m).

(7) The mesylate (1.5 g, 3.2 mmol) in dimethylformamide (5 ml) was treated with sodium azide (315 mg, 4.8 mmol) and heated to 90°C for 6 hrs. The mixture was treated with water (80 ml), and extracted with diethyl ether (3 x 50 ml), dried (MgSO₄) and evaporated to dryness. The solid was triturated with ether to give the *cis* azide (1.4 g) ¹H NMR (CDCl₃) 7.40-7.34 (4H, m), 7.12-7.03 (2H, m), 6.90-6.83 (1H, m), 3.78-3.76 (1H, m), 2.62-2.41 (4H, m), 1.97-1.91 (2H, m) and 1.51-1.41 (2H, m).

20 (8) The azide (1 g, 2.55 mmol) in tetrahydrofuran (10 ml) and water (1 ml), was treated with triphenylphosphine (740 mg, 2.8 mmol) at room temperature for 15 mins, water (5 ml) was added and the mixture was heated at reflux for 4 hrs. After cooling to room temperature and passage through SCX Varian Bond Elut™ cartridge, the basic fraction was evaporated to give the primary amine. ¹H NMR (CDCl₃) 7.35 (4H, s), 7.12-7.01 (2H, m), 6.88-6.81 (1H, m), 3.13-3.11 (1H, m), 2.64-2.44 (4H, m), 1.78-1.68 (2H, m) and 1.52-1.39 (2H, m). MS MH⁺ 386(388).

Intermediate B

30 4-(2,5-difluorophenyl)-4-(4-trifluoromethylbenzenesulfonyl)cyclohexylamine




Prepared as for Intermediate A, using 4-(trifluoromethyl)thiophenol in step (1), except that the borohydride reduction of step (5) was carried out at -20°C.

5 MS (ES+) MH+ 420

Intermediate C

4-(2,5-difluorophenyl)-4-(6-trifluoromethyl-pyridine-3-sulfonyl)cyclohexylamine



10

- (1) A solution of 3-amino-6-(trifluoromethyl)pyridine (1.62 g, 0.01 mol) in concentrated hydrochloric acid (1.7 mL), was treated with ice (2 g) and cooled to 0°C. Sodium nitrite (0.71 g, 0.01 mol) in water (2 mL) was added slowly, the reaction mixture stirred for 5 minutes at 0°C then treated slowly with a solution of potassium ethyl xanthate (1.92 g, 0.012 mol) in ethanol-water. The reaction mixture was heated at 50-55°C for 30 minutes, cooled and diluted with diethyl ether and water. The organic layer was washed with brine, dried ($MgSO_4$) and evaporated *in vacuo*. The resulting xanthate was dissolved in ethanol (30 mL) and treated with potassium hydroxide (3 g) and refluxed (90°C) for 2 h. After cooling and filtering, the filtrate was acidified with citric acid and diluted with diethyl ether. The organic layer was washed with brine, dried ($MgSO_4$) and

evaporated *in vacuo*. Purification by column chromatography on silica gave the (trifluoromethyl)pyridinethiol as a yellow oil (0.79 g, 44%).

¹H NMR (360 MHz, CDCl₃) δ 8.57 (1H, d, J = 2.0 Hz), 7.74 (1H, dd, J = 8.1, 2.0 Hz), 7.54 (1H, d, J = 8.1 Hz), 3.62 (1H, s).

5 (2) This thiol (0.5 g, 2.8 mmol) was reacted first with 2,5-difluorobenzyl bromide and subsequently with 3-chloroperoxybenzoic acid by the procedure described for Intermediate A to give the pyridyl benzyl sulfone as a white powder (0.82 g, 87% over 2 steps).

10 ¹H NMR (400 MHz, CDCl₃) δ 8.93 (1H, d, J = 2.1 Hz), 8.18 (1H, dd, J = 8.1, 2.1 Hz), 7.80 (1H, d, J = 8.1 Hz), 7.21-7.17 (1H, m), 7.10-7.04 (1H, m), 6.93-6.88 (1H, m), 4.46 (2H, s).

15 (3) This sulfone (50 mg, 0.15 mmol) in tetrahydrofuran (5 mL) at 0°C was treated with potassium *tert*-butoxide (17 mg, 0.15 mmol), then with 2,2-bis(2-iodoethyl)-1,3-dioxolane (H. Niwa et al, J. Am. Chem. Soc., 1990, 112, 9001) (86 mg, 0.23 mmol), stirred for 1 h at room temperature and then for 1 h at 70°C. The cooled reaction mixture was treated with more potassium *tert*-butoxide (1.2 equivalents) and 2,2-bis(2-iodoethyl)-1,3-dioxolane (0.3 equivalents). After heating at 70°C for 1h, then cooling to room temperature, the reaction mixture was diluted with diethyl ether and water, the layers separated and the organic layer washed with water and brine, dried (MgSO₄) and evaporated *in vacuo*. Purification by column chromatography on silica gave the desired cyclohexanone cyclic ketal (38 mg, 56%) as a white solid.

20 ¹H NMR (360 MHz, CDCl₃) δ 8.68 (1H, d, J = 2.0 Hz), 7.92 (1H, dd, J = 2.0, 8.1 Hz), 7.73 (1H, d, J = 8.1 Hz), 7.19-7.07 (2H, m), 6.90-6.82 (1H, m), 3.99-3.88 (4H, m), 2.7 (2H, vbrm), 2.5 (2H, vbrappt), 1.85 (2H, brappd), 1.54-1.26 (2H, m).

25 (4) This ketal (30 mg, 0.065 mmol) was heated at 50°C overnight with *p*-toluenesulfonic acid (15 mg) in 80% acetic acid-water. The reaction mixture was partitioned between diethyl ether and water and the organic layer washed with saturated aqueous sodium hydrogencarbonate solution

and brine, dried (MgSO_4) and evaporated *in vacuo*. Purification by column chromatography on silica gave the cyclohexanone (25 mg, 92%) as a white solid.

^1H NMR (400 MHz, CDCl_3) δ 8.67 (1H, d, $J = 2.0$ Hz), 7.97 (1H, dd, $J = 8.1, 2.0$ Hz), 7.77 (1H, d, $J = 8.1$ Hz), 7.28-7.16 (2H, m), 6.99-6.90 (1H, m), 3.01-2.97 (2H, m), 2.68-2.57 (4H, m), 2.26-2.17 (2H, m).

(5) The cyclohexanone was converted to the title amine by the procedure of Intermediate A, except that the borohydride reduction was carried out at -78°C . M/Z 421 (MH^+).

10

Sulfonyl Chlorides

The sulfonyl chlorides used in these examples were typically commercially available, or available by literature routes. Representative syntheses include the following:

15

2-methyl-1-propanesulfonyl chloride

To 2-methyl-1-propanethiol (200 mg, 2.22 mmol) at 0°C in acetonitrile under nitrogen was added KNO_3 (561 mg, 5.5 mmol) then sulfonyl chloride (0.45 ml, 5.5 mmol). The reaction mixture was stirred at 0°C for 3h, diluted with NaHCO_3 and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (MgSO_4) and evaporated to give the sulfonyl chloride (293 mg, 95%) ^1H NMR (CDCl_3) 3.65-3.63 (2H, d, $J = 6.5$ Hz), 2.55-2.49 (1H, m), 1.19-1.18 (6H, d, $J = 6.7$ Hz)

25

2-chlorosulfonyl-1-methylimidazole


Bleach (12% w/w aq, 110 ml) was cautiously added dropwise to a solution of 2-mercapto-1-methylimidazole (2.0 g) in conc. H_2SO_4 (50 ml) cooled to 0°C . After stirring 30 minutes at 0°C the mixture was diluted with H_2O (30 ml) and dichloromethane (30 ml). The aqueous layer was re-extracted with dichloromethane and the combined organic layers dried (MgSO_4) and evaporated to give the product as an oil (730 mg).

5-chlorosulfonyl-1-methyltetrazole

Cl₂(g) was bubbled through a solution of 5-mercaptop-1-methyltetrazole (1.518 g) in 2N HCl (25 ml) at 0°C. After 15 minutes the solid precipitate 5 (880mg) was filtered off and washed with H₂O.

Example 1

methanesulfonic acid, N-[4-(4-chlorobenesulfonyl)-4-(2,5-difluorophenyl)cyclohexyl]-amide



10


Methanesulfonyl chloride (24 µL, 0.31 mmol) was added to a solution of Intermediate A (100 mg, 0.28 mmol) and triethylamine (77 µL, 0.56 mmol) in dichloromethane (1.5 ml) at 0°C. After stirring at ambient temperature for 12 hours, the reaction was partitioned between water (50 ml) and dichloromethane (50 ml), the phases separated and the aqueous layer washed twice more with dichloromethane. The combined organic layers were washed with 1N HCl. the acidic layer extracted twice with dichloromethane and the combined organics dried over K₂CO₃ and concentrated. Flash column chromatography eluting with 60/40 hexane / ethyl acetate afforded the title compound (88.5 mg).

¹H NMR CDCl₃ 7.34 (4H, m), 7.06 (2H, m), 6.85 (1H, m), 4.72 (1H, d, J = 6.67 Hz), 3.65 (1H, m), 3.00 (3H, s), 2.58 (2H, m), 2.42 (2H, t, J = 13.68 Hz), 2.00 (2H, m), 1.60 (1H, m), 1.53 (1H, m).






MS(ES⁻) [M-H] 462, 464.

25

The following examples were prepared by the same procedure:



Example	R	MS (ES⁻ (MH⁻) unless otherwise stated)
2	CH ₂ CF ₃	530, 532
3	nPr	490, 492
4	benzyl	538, 540
5	phenyl	524, 526
6	2-thienyl	530, 532
7	ethyl	476, 478
8	5-chloro-2-thienyl	566, 568 (M+H) ⁺
9	n-butyl	504, 506
10	2-fluorophenyl	542, 544
11	3-fluorophenyl	542, 544
12	4-fluorophenyl	542, 544
13	2-pyridyl	525, 527
14	5-methyl-2-thienyl	546, 548 (MH) ⁺
15	5-isothiazolyl	531, 533
16	4-chloro-2-thienyl	564, 566, 568
17	2-(trifluoromethyl)phenyl	616/618[M+Na] ⁺
18	CH ₂ CH(CH ₃) ₂	506, 508[MH] ⁺
19	CH ₂ SO ₂ Me	542, 544[MH] ⁺
20	2-methylphenyl	540, 542[MH] ⁺


Example	R	MS (ES ⁻ (MH ⁻) unless otherwise stated)
21		529, 531
22	2-thiazolyl	531, 533
23	chloromethyl	494, 496, 498
24	2-furyl	514, 516
25	2-chlorophenyl	558, 560
26	2-cyanophenyl	549, 551
27		543, 545
28	3-thienyl	530, 532
29	3-chloropropyl	524, 526
30		532 ,543[MH] ⁺
31		517, 519[MH] ⁺
32	3-chloro-2-thienyl	564, 566
33		530, 532[MH] ⁺

Example	R	MS (ES ⁻ (MH ⁻) unless otherwise stated)
34		530, 532 [MH] ⁺
35		528, 530
36	2-bromophenyl	430 [MH-4-Cl-PhSO ₂] ⁺
37		*

* ¹H NMR (DMSO) 7.93 (1H, d, J = 3.9 Hz), 7.64-7.62 (2H, d, J = 8.6 Hz), 7.37-7.27 (3H, m), 7.21-7.09 (2H, m), 3.75 (3H, s), 3.15 (1H, d, J = 2.0 Hz), 2.43-2.44 (2H, m), 2.32 (2H, dd, J = 12.1 and 0.8 Hz), 2.28 (3H, s), 1.77 (5 (2H, dd, J = 13.3 and 1.2 Hz), 1.29-1.22 (2H, m)

Example 38

{N-[4-(4-chlorobzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amino}acetic acid, methyl ester




10

To a stirred solution of chlorosulfonyl acetyl chloride (1g of 95% purity, 5.7 mmol) in tetrahydrofuran (20 ml) under nitrogen was added methanol (0.23 ml, 5.7 mmol). The reaction mixture was stirred at ambient

temperature over 2h. After this time, the reaction was evaporated to afford the chlorosulfonyl methyl ester which was coupled to Intermediate A (100 mg, 0.28 mmol) by the procedure of Example 1 to afford the desired product. ^1H NMR (CDCl_3) 7.39-7.32 (4H, m), 7.08-7.04 (2H, m), 6.89-6.82 (1H, m), 5.38 (1H, d, $J = 5.6$ Hz), 4.03 (2H, s), 3.84 (3H, s), 3.64-3.59 (1H, m), 2.62-2.24 (2H, m), 2.49-2.42 (2H, m), 2.08-2.04 (2H, m), 1.59-1.49 (2H, m); $m/z(\text{ES}^-) = 520/522$

Example 39


methanesulfinic acid, N-[4-(4-chlorobzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide



Prepared by the procedure of Example 1 using methyl sulfinyl chloride (prepared from dimethyldisulfide following the procedure described in Corey et. al *J.American Chem. Soc.*, 1968, 90(20), 5548-5552). $m/z(\text{ES}^+) = 272[\text{M}-\text{ArSO}_2^-]^+$, $m/z = 448[\text{MH}]^+$ and $m/z = 470[\text{M}+\text{Na}]^+$

Example 40

3-bromothiophene-2-sulfonic acid, N-[4-(4-chlorobzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide




3-Bromothiophene (16.1 g, 98.8 mmol) at -78°C in dichloromethane (40 ml) under nitrogen was treated dropwise with chlorosulfonic acid (40 ml, 602 mmol) over 1h. The reaction mixture was stirred for 3h at ambient temperature, then cautiously poured onto ice (1500 ml) and extracted with dichloromethane (3x150 ml). The combined organic layers were washed with brine, dried (MgSO_4) and evaporated to give a residue (18 g) which was purified using preparative thin layer chromatography eluting with 3% ethyl acetate:hexane to afford 4-bromo-2-thiophenesulfonylchloride (320mg) as the minor product, and 3-bromo-2-chlorothiophenesulfonyl chloride as the major product (4.5 g). The 3-bromo-isomer was coupled to Intermediate A by the procedure of Example 1.

^1H NMR (CDCl_3) 7.50-7.48 (2H, dd, $J = 8.8$ and 1.5 Hz), 7.39-7.31 (4H, m), 7.07-7.02 (2H, m), 6.87-6.80 (1H, m), 5.14-5.12 (1H, d, $J = 6.5$ Hz), 3.53-3.49 (1H, m), 2.53-2.56 (2H, m), 2.41-2.34 (2H, t, $J = 13.6$ Hz), 1.90-1.86 (2H, m), 1.68-1.45 (2H, m) and $m/z(\text{ES-}) = 610, 612$

Example 41

4-bromothiophene-2-sulfonic acid, N-[4-(4-chlorobzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide

20




Prepared as for Example 40, using the 4-bromo-2-thiophenesulfonyl chloride.

^1H NMR (CDCl_3) 7.50-7.49 (1H, d, $J = 5.2$ Hz), 7.41-7.32 (4H, m), 7.13-7.12 (1H, d, $J = 5.2$ Hz), 7.06-7.01 (2H, m), 6.83-6.79 (1H, m), 5.42-5.40 (1H, d, J

= 6.6 Hz), 3.49-3.45 (1H, m), 2.57-2.54 (2H, m), 2.44-2.37 (2H, m), 1.91-1.87 (2H, m), 1.59-1.41 (2H, m) and m/z(ES-) = 610, 612

Example 42

- 5 2-methoxy-5-chlorobenzenesulfonic acid, N-[4-(4-chlorobenzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide




To a solution of 2-methoxybenzenethiol (200 mg, 1.43 mmol) in acetonitrile under nitrogen at 0°C was added KNO₃ (361 mg, 3.6 mmol) then sulfonyl chloride (0.29 ml, 3.6 mmol). The reaction mixture was stirred at 0°C for 5h, then diluted with NaHCO₃ and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (MgSO₄) and evaporated to give a residue (264 mg) which was coupled in the same manner as in Example 1 to afford a 1:1 mixture (80 mg) which was purified using preparative thin layer chromatography eluting with ethyl acetate:dichloromethane:hexane 1:1:2 to give the 2-methoxy-5-chlorophenylsulfonyl derivative (40 mg).

M/z(ES-) = 588/590

20 **Example 43**

- 2-methoxybenzenesulfonic acid, N-[4-(4-chlorobenzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide




Isolated from the product mixture of Example 42 using preparative thin layer chromatography eluting with ethyl acetate:dichloromethane:hexane
5 1:1:2.

Yield 20mg. M/z(ES-) = 554/556

Example 44

[4-(4-Chlorobenzensulfonyl)-4-(2,5-

10 difluorophenyl)cyclohexyl]aminosulfonyl-acetamide




The ester of Example 38 (40 mg, 0.07 mmol) in ethanol (1.5 ml) was treated with NH₃ (1 ml of 25% aqueous solution). The reaction mixture was stirred at ambient temperature for 2h and evaporated to give a residue (40 mg) which was purified using preparative plate thin layer chromatography eluting with ethyl acetate:hexane 2:1 to yield the desired product (10 mg).

¹H NMR (CDCl₃) 7.38-7.31(4H, m), 7.08-7.03 (2H, m), 6.89-6.83 (1H, m), 6.54 (1H, s), 6.06 (1H, s), 5.78 (1H, d, J = 6.1 Hz), 3.97 (1H, s), 3.65-3.63 (1H, m), 2.57-2.43 (4H, m), 2.10-2.04 (2H, m), 1.58-1.50 (2H, m); M/z(ES-) = 505/507

Example 45

2-hydroxyethanesulfonic acid, N-[4-(4-chlorobenzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide




5

LiAlH₄ (0.29 ml of 1M solution in tetrahydrofuran, 0.29 mmol) in tetrahydrofuran (3 ml) at 0°C under nitrogen was treated dropwise with a solution of the ester of Example 38 (50 mg, 0.1 mmol) in tetrahydrofuran (9 ml). The reaction mixture was stirred at ambient temperature for 3 days, quenched with aqueous sodium sulfate then partitioned between water and ethyl acetate. The combined organic layers were dried (MgSO₄) and evaporated to give a residue (47 mg) which was purified using preparative thin layer chromatography eluting with ethyl acetate:hexane 2:1 to give the desired product (12 mg). ¹H NMR (CDCl₃) 7.38 (2H, d, J = 9.2 Hz), 7.32 (2H, d, J = 8.8 Hz), 7.08-7.04 (2H, m), 6.88-6.84 (1H, m), 5.39 (1H, d, J = 6.4 Hz), 4.51-4.09 (2H, m), 3.65-3.63 (1H, m), 3.28 (2H, t, J = 5.2 Hz), 2.83 (1H, t, J = 5.6 Hz), 2.56-2.44 (4H, m), 2.05-2.20 (2H, m), 1.57-1.50 (2H, m); M/z(ES-) = 492/494

20 **Example 46**

cyanomethanesulfonic acid, N-[4-(4-chlorobenzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide




To a solution of the amide of Example 44 (80 mg, 0.16 mmol) in toluene (10 ml) under nitrogen was added thionyl chloride (23 μ L, 0.32 mmol) and a catalytic amount of dimethylformamide. After refluxing for 16h, the

- 5 reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried ($MgSO_4$) and evaporated to give a residue (78 mg) which was purified using preparative thin layer chromatography eluting with ethyl acetate:hexane 1:2 to give the desired product (42 mg). 1H NMR (CDCl₃) 7.39-7.31 (4H, m), 7.08-7.04 (2H, m), 6.88-6.84 (1H, m), 6.24 (1H, d, J = 6.1 Hz), 4.12 (2H, s), 3.09-3.07 (1H, m), 2.62-2.46 (4H, m), 2.11-2.04 (2H, m), 1.65-1.57 (2H, m).
- 10 M/z(ES-) = 487/489

15 **Example 47**

trifluoromethanesulfonic acid, N-[4-(4-chlorobenzensulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide




- Intermediate A (110 mg, 0.29 mmol) in dichloromethane (3 ml) cooled to
20 0°C was treated with triethylamine (99 μ L, 0.43 mmol) followed by triflic anhydride (117 μ L, 0.71 mmol). The reaction was stirred at 0°C for 2.5 hours, slowly warming to ambient temperature, then diluted with ethyl

acetate, washed with 2N sodium hydroxide, dried (MgSO_4) and evaporated to an orange oil which was purified by chromatography 15% ethyl acetate / hexane to yield a white solid (16 mg). ^1H NMR (360MHz, CDCl_3) δ 7.39-7.30 (4H, m), 7.09-7.04 (2H, m) 6.88-6.81 (1H, m), 5.86-5.84 (1H, m), 3.82-5 3.80 (1H, m), 2.64-2.42 (4H, m), 2.07-2.02 (2H, m), 1.66-1.59 (2H, m).
m/z = 540, 542[M + Na]⁺

Example 48


methanesulfonic acid, N-[4-(4-chlorobzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-N-methyl-amide
10



The product of Example 1 (52 mg, 0.11 mmol) in tetrahydrofuran (3 ml), cooled to 0°C was treated with sodium hydride (11 mg, 0.28 mmol). After 10 minutes methyl iodide was added (70 μL , 1.1 mmol) and the reaction
15 heated to 50°C for 4 hours, then extracted into ethyl acetate and washed with H_2O , dried (MgSO_4) and evaporated. Product was purified by chromatography (25% ethyl acetate / hexane). ^1H NMR (400MHz, CDCl_3) δ 7.36-7.26 (4H, m), 7.04-7.01 (2H, m), 6.79-6.71 (1H, m), 3.91-3.84 (1H, m), 3.24-3.19 (2H, d, broad), 2.91 (3H, s), 2.86 (3H, s), 2.64-2.57 (2H, dd, J = 12.5, J = 3.8), 2.06-2.01 (2H, m), 1.85-1.76 (2H, m). m/z = 500, 502 [MNa]⁺


Example 49

methanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-trifluoromethylbenzenesulfonyl)-cyclohexyl]-amide
25



Intermediate B (150 mg, 0.36 mmol) was suspended in dry dichloromethane (5 ml) under nitrogen. Triethylamine (109 μ l, 0.79 mmol) and methane sulfonyl chloride (42 μ l, 0.54 mmol) were added and the reaction stirred for 16 h, diluted with dichloromethane, washed with water, brine, dried ($MgSO_4$) filtered and evaporated. The residue was purified by flash chromatography eluting with *iso*-hexane/ethyl acetate (1:1) to give a white solid (75 mg). 1H NMR δ (ppm) ($CDCl_3$): 1.53 (2H, m), 2.05 (2H, m), 2.48 (4H, m), 3.04 (3H, s), 3.64 (1H, m), 5.14 (1H, br), 6.84 (1H, m), 7.05 (2H, m), 7.54 (2H, d, $J = 7.8$ Hz), 7.66 (2H, d, $J = 7.8$ Hz). MS [MH $^+$] 499

The following examples were prepared by the same procedure, using the appropriate sulfonyl chloride:



15


Example	R	MS (MH $^+$) unless otherwise stated
50	2-furyl	[MNa $^+$] 572
51	ethyl	513
52	CH_2SO_2Me	[MNa $^+$] 598

Example	R	MS (MH ⁻) unless otherwise stated
53		[MH ⁺] 564
54	5-isothiazolyl	[MH ⁺] 567
55	2-pyridyl	[MNa ⁺] 583, [MH ⁺] 561
56	5-chloro-2-thienyl	[MH ⁺] 600, 602
57	n-propyl	[MH ⁺] 526
58	2-thienyl	[MH ⁺] 566.
59	6-chloro-3-pyridyl	[MH ⁺] 596, 598
60	3-thienyl	[MH ⁺] 566
61*	vinyl	[MH ⁺] 510, [MH-SO ₂ Ar ⁺] 300

* - prepared using 2-chloroethanesulfonyl chloride. ¹H NMR δ (ppm) (CDCl₃): 1.49-1.50 (1H, m), 1.57-1.58 (1H, m), 1.97-2.01 (2H, m), 2.40-2.64 (4H, m), 3.50-3.54 (1H, m), 4.59 (1H, dd, J = 6.0, 0.7 Hz), 5.95 (1H, d, J = 5 Hz), 6.24 (1H, d, J = 9.8 Hz), 6.53 (1H, dd, J = 9.7 Hz, 6.8 Hz) 6.79-6.86 (1H, m), 7.04-7.10 (2H, m), 7.52 (2H, d, J = 7.8 Hz) 7.66 (2H, d, J = 7.8 Hz).

Example 62

- 10 trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-trifluoromethyl-benzenesulfonyl)-cyclohexyl]-amide




Intermediate B (170 mg, 0.41 mmol) in dry dichloromethane (5 ml) under nitrogen was treated at 0°C with triethylamine (80 µl, 0.62 mmol) and triflic anhydride (133 µl, 0.82 mmol). The reaction was allowed to warm to room temperature, stirred for 3 h. diluted with dichloromethane, washed 5 with water, brine, dried (MgSO_4) filtered and evaporated. The residue was purified by flash chromatography eluting with *iso*-hexane/ethyl acetate (1:1) to give a white solid (60 mg).

10 ^1H NMR δ (ppm) (DMSO): 1.46-1.53 (2H, m), 1.81 (1H, s), 1.84 (1H, s), 2.41 (2H, t, J = 13.1 Hz), 2.56-2.59 (1H, m), 2.59 (1H, d, J = 2.7 Hz), 3.64 (1H, s), 7.10-7.23 (2H, m), 7.30-7.36 (1H, m), 7.60 (2H, d, J = 8.2 Hz), 7.94 (2H, d, J = 7.6 Hz), 9.77 (1H, d, J = 7.6 Hz).

Example 63

15 2-(morpholin-4-yl)ethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-trifluoromethyl-benzenesulfonyl)-cyclohexyl]-amide



The vinyl sulfonamide of Example 61 (50 mg, 0.098 mmol) in dry dimethylformamide (3 ml) was treated with morpholine (130 µl, 1.47 mmol) and the reaction heated at 40°C for 18 h, diluted with water, and 20 extracted with ethyl acetate (x3). The combined organics were washed with water, brine, dried (MgSO_4), filtered and evaporated. The residue was purified by flash chromatography eluting with ethyl acetate and 1% triethylamine to give a white solid (28 mg).


25 ^1H NMR δ (ppm) (CDCl_3): 1.53-1.61 (2H, m), 2.02-2.06 (2H, m), 2.49 -2.58 (8 H, m), 2.91 (2 H, t, J = 6.5 Hz), 3.21 (2 H, t, J = 6.5 Hz), 3.68-3.72 (1 H, m), 3.77 (4 H, t, J = 4.7 Hz), 5.55 (1 H, d, J = 5.1 Hz), 6.83 (1 H, q, J = 2.5 Hz), 7.05-7.09 (2 H, m), 7.52 (2 H, d, J = 7.9 Hz), 7.65 (2 H, d, J = 7.9 Hz).

MS [MH⁺] 597

Example 64

6-(morpholin-4-yl)pyridine-3-sulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-

5 trifluoromethyl-benzenesulfonyl)-cyclohexyl]-amide




The product from example 59 (15 mg, 0.025 mmol) in ethanol (2 ml) was treated with morpholine (20 μ L) and heated to reflux for 18 hours. The solvent was removed and the product purified by silica gel chromatography eluting the title compound with ethyl acetate/ hexane mixtures, 16 mg. ¹H NMR δ (ppm) (DMSO), 8.40 (1H, d, J = 2.5 Hz), 7.94 (2H, d, J = 8.1 Hz), 7.83 (1H, dd, J = 2.5, 9.1 Hz), 7.71 (1H, d, J = 4.6 Hz), 7.59 (2H, d, J = 8.1 Hz), 7.26-7.33 (1H, m), 7.07-7.20 (2H, m), 6.93 (1H, d, J = 9.1 Hz), 3.67-3.69 (8H, m), 2.50 (2H, m), 3.05 (1H, dd, J = 1.9, 3.3 Hz), 2.30-2.37 (2H, m), 1.62-1.76 (2H, m) and 1.19-1.27 (2H, m).

Example 65

1,1-dimethylethanesulfinic acid, N-[4-(2,5-difluorophenyl)-4-(4-

trifluoromethyl-benzenesulfonyl)-cyclohexyl]-amide




Intermediate B (0.73 g, 1.75 mmol) and 1,1-dimethylethyl sulfinamide (0.21g, 1.75 mmol) in tetrahydrofuran (20 ml) was treated with titanium (IV) ethoxide (0.36 ml, 1.75 mmol) and heated to 80°C for 18 hours. The reaction was quenched with water (0.35 ml) and stirred for 10 minutes
5 before filtering through Celite™. The sulfinimine was cooled to -30°C and treated with L-Selectride™ (1.75 ml, 1.0 mmol solution), and stirred for 2 hours whilst warming to -5°C. The reaction was then quenched with methanol (2 ml), and partitioned between ethyl acetate (50 ml) and brine (50 ml), dried (MgSO₄) and evaporated to dryness. The product was
10 purified by silica gel chromatography eluting with ethyl acetate/ hexane mixtures. Yield 120 mg. ¹H NMR δ(ppm) (CDCl₃), 7.68 (2H, d, J = 7.5 Hz), 7.61 (2H, d, J = 7.5 Hz), 7.05-7.15 (2H, m), 6.84-6.90 (1H, m), 3.56 (1H, q, J = 2.7 Hz), 3.03 (1H, s), 2.62-2.42 (4H, m), 2.13-2.18 (1H, m), 1.83-1.76 (1H, m), 1.70-1.65 (1H, m), 1.50-1.40 (1H, m) and 1.24 (9 H, s). MS MH = 524.

15

Example 66

1,1-dimethylethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-trifluoromethyl-benzenesulfonyl)-cyclohexyl]-amide




20 The product from Example 65 (110 mg, 0.21 mmol) in dichloromethane (2 ml) was treated with m-chloroperoxybenzoic acid (86 mg, 0.25 mmol, 50% w/w) and stirred for 1 hour. The reaction was diluted with dichloromethane (25 ml) and washed with sodium bisulfite (30 ml, 10% solution), saturated sodium bicarbonate (30 ml) and brine (20 ml), dried
25 over magnesium sulfate, evaporated and purified by silica gel chromatography eluting the desired product with ethyl acetate/ hexane mixtures, 80 mg. ¹H NMR δ(ppm) (CDCl₃), 7.66 (2H, d, J = 7.5 Hz), 7.53

(2H, d, $J = 7.5$ Hz), 7.08-7.04 (2H, m), 6.90-6.78 (1H, m), 4.32 (1H, d, $J = 7.9$ Hz), 3.64-3.55 (1H, m), 2.62-2.53 (2H, m), 2.48-2.38 (2H, m), 2.21-1.98 (2H, m), 1.65-1.54 (2H, m), 1.40 (9H, s), MS $MH = 540$.

5 **Example 67**


2-(pyrrolidin-1-yl)ethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-trifluoromethylbenzenesulfonyl)cyclohexyl]-amide



To the vinyl sulfonamide prepared in example 61 (100 mg, 0.19 mmol) in
10 dry dimethylformamide (3 ml) was added pyrrolidine (0.25 ml, 2.49 mmol).
The reaction was heated at 40°C for 4 h, diluted with water, and extracted
with ethyl acetate (x3). The combined organics were washed with water,
brine, dried ($MgSO_4$), filtered and evaporated. The residue was purified by
flash chromatography eluting with dichloromethane/methanol (9:1) to give
15 a white solid (60 mg). MS $[MH^+] 581$

Example 68

3-{[4-(2,5-difluorophenyl)-4-(4-trifluoromethylbenzenesulfonyl)cyclohexyl]aminosulfonyl}-thiophene-2-carboxylic acid, methyl ester




20

Prepared from Intermediate B (200 mg, 0.48 mmol) by the procedure of Example 49. The product was purified by flash chromatography eluting with *iso*-hexane/ethyl acetate (3:1) to give a white solid (125 mg).

¹H NMR δ (ppm) (CDCl₃): 1.34-1.43 (2H, m), 1.84-1.88 (2H, m), 2.33-2.55 (4H, m), 3.49 (1H, dd, J = 3.0, 5.4 Hz), 4.03 (3H, s), 6.72 (1H, d, J = 6.0 Hz), 6.76-6.83 (1H, m), 6.98-7.07 (2H, m), 7.51-7.57 (4H, m), 7.65-7.67 (2H, d, J = 7.8 Hz).

5

Examples 69-74




The following sulfonamides were prepared by the procedure of Example 1 using Intermediate C and the appropriate sulfonyl chloride.

Example	R	MS (MH ⁺)
69	methyl	499
70	2-thienyl	567
71	CF ₃	553
72	5-isothiazolyl	568
73	n-propyl	527
74*	2-chloro-2-propyl	561, 563

10 *Isopropylsulfonyl chloride was used.

Example 75

trifluoromethanesulfonic acid, N-[4-(5-bromo-2-fluorophenyl)-4-(6-trifluoromethyl-pyridine-3-sulfonyl)-cyclohexyl]-amide




Prepared by the procedures of Intermediate C (using 2-fluoro-5-bromobenzyl bromide in Step 2) and Example 1 (using trifluoromethanesulfonyl chloride). M/Z = 613, 615 (MH⁺).

5

Example 76

trifluoromethanesulfonic acid, N-[4-(5-cyano-2-fluorophenyl)-4-(6-trifluoromethyl-pyridine-3-sulfonyl)-cyclohexyl]-amide




- 10 A solution of the compound prepared in Example 75 (45 mg) was treated with copper cyanide (4 equivalents), pyridine (1 drop) and dimethylformamide (3 ml) and heated at 180°C overnight. The reaction was diluted with ethyl acetate and water and filtered. The organic layer of the filtrate was washed with water and brine and dried, filtered and evaporated in vacuo. Purification by column chromatography gave the nitrile (27 mg, 66%). M/Z = 559 (MH⁺).
- 15

Example 77

trifluoromethanesulfonic acid, N-[4-(2-fluoro-5-methyl-phenyl)-4-(6-

- 20 trifluoromethyl-pyridine-3-sulfonyl)-cyclohexyl]-amide




The compound prepared in Example 75 (50 mg) in dioxane was treated with cesium fluoride (2.2 equivalents), tri-tert-butylphosphine (12 mol%), tetramethyltin (2 equivalents), and Pd₂(dba)₃ (3 mol%) and heated at

- 5 100°C for 3 h. The reaction mixture was cooled, diluted with ether, filtered and the filtrate evaporated in vacuo. Purification by column chromatography gave the toluene derivative (13 mg, 29%). M/Z = 549 (MH⁺).

10 **Example 78**

trifluoromethanesulfonic acid, N-[4-(2-fluoro-5-(hydroxymethyl)-phenyl)-4-(6-trifluoromethyl-pyridine-3-sulfonyl)-cyclohexyl]-amide




- (1) A solution of the compound prepared in Example 75 (50 mg) in
15 dioxane was treated with CsF (2.2 equivalents), tri-tert-butylphosphine (12 mol%), tributylvinyltin (2 equivalents), and Pd₂(dba)₃ (3 mol%) and heated at 100°C for 2 h. The reaction mixture was cooled, diluted with ether, filtered and the filtrate evaporated in vacuo. Purification by column chromatography gave the styrene (30 mg).
- 20 (2) A solution of the foregoing styrene in dichloromethane (4 ml) and methanol (1 ml) was cooled to -78°C and treated with excess ozone. The reaction mixture was quenched with dimethyl sulfide, warmed to room temperature and evaporated in vacuo to give the crude aldehyde.

(3) A solution of the foregoing aldehyde in ethanol (3 ml) was cooled to -78°C and treated with sodium borohydride (2 equivalents) and stirred for 3 h. The reaction mixture was quenched with citric acid, warmed to room temperature and diluted with ethyl acetate. The organic layer was 5 washed with water and brine, dried (MgSO_4), filtered and evaporated. Purification by column chromatography gave the alcohol (16 mg, 53%).
 $\text{M/Z} = 547 (\text{M-OH}+\text{H}^+)$.

Example 79


- 10 trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-vinylbenzenesulfonyl)-cyclohexyl]-amide



Nitrogen was bubbled through a solution containing the product of Example 47 (1.0 g, 1.93 mmol), tri-*t*-butylphosphine (0.1 M in dioxane, 190 15 μl , 0.19 mmol), cesium fluoride (0.65 g, 4.28 mmol) and $\text{Pd}_2(\text{dba})_3$ (0.10 g, 0.11 mmol) in dioxane (8 ml) in a sealed tube for 5 minutes. Tributyl(vinyl)tin (0.65 g, 2.05 mmol) was added and the mixture heated at 100°C for 2 hours. This sequence was repeated on the same scale a further four times. All five reaction mixtures were combined and diluted 20 with diethyl ether (50 ml) and filtered through a silica gel pad, evaporated *in vacuo* to give crude product which was chromatographed on silica eluting with 5-20% ethyl acetate / isohexane, then azeotroped with dichloromethane to give the desired product (2.67 g, 55%). $^1\text{H NMR}$ (CDCl_3 , 360 MHz): 1.59-1.70 (2H, m), 2.02-2.06 (2H, m), 2.44 (2H, t, $J = 12.7$ Hz), 2.61-2.65 (2H, m), 3.78 (1H, m), 5.47 (1H, d, $J = 10.9$ Hz), 5.82 25 (1H, bd, $J = 7.8$ Hz), 5.88 (1H, d, $J = 17.5$ Hz), 6.68-6.87 (1H, m), 7.01-7.08 (2H, m), 7.32 (2H, d, $J = 8.3$), 7.40 (2H, d, $J = 8.1$), 10.10 (1H, s)

Example 80

trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-formylbenzenesulfonyl)-cyclohexyl]-amide




5

Ozone was bubbled through a solution of the product of Example 79 (2.5 g, 4.9 mmol) in dichloromethane / methanol (125 ml / 25 ml) at -78°C until a blue colour was observed. Oxygen was bubbled through the mixture for 10 minutes until the blue colour disappeared. The mixture was quenched with dimethyl sulfide (2.16 ml, 29.5 mmol), allowed to warm to room temperature and stirred for 16 hours. The mixture was concentrated *in vacuo* to give an oil (2.80 g), which was chromatographed on silica, eluting with 20% ethyl acetate / isohexane to give the aldehyde (2.18 g, 87%). ^1H NMR (CDCl_3 , 360 MHz): 1.59-1.70 (2H, m), 2.04-2.09 (2H, m), 2.48 (2H, t, $J = 12.3$), 2.61-2.68 (2H, m), 3.82 (1H, m), 5.75 (1H, d, $J = 7.7$), 6.77-6.86 (1H, m), 7.07-7.11 (2H, m), 7.57 (2H, d, $J = 8.1$), 7.90 (2H, d, $J = 8.3$), 10.10 (1H, s)

Example 81


20 4-{[1-(2,5-difluorophenyl)-4-[(trifluoromethanesulfonyl)aminol]-cyclohexanesulfonyl}-benzaldehyde oxime



A solution of the product of Example 80 (0.40 g, 0.80 mmol), hydroxylamine hydrochloride (0.16 g, 2.4 mmol) and sodium acetate (0.19 g, 2.4 mmol) in ethanol (60 ml) was heated at reflux for 16 hours and stirred at room temperature for 32 hours. The mixture was evaporated *in vacuo* and extracted with ethyl acetate (50 ml). The organic phase was washed with brine (sat. 40 ml), dried (magnesium sulfate) and evaporated *in vacuo*. The crude product was chromatographed on silica, eluting with 20-28% ethyl acetate / isohexane to give the oxime (0.36 g, 87%). ¹H NMR (DMSO, 360 MHz): 1.49 (2H, bt, J = 12.3), 1.82 (2H, bd, J = 14.0), 2.40 (2H, bt, J = 13.8), 2.50-2.60 (2H, m), 3.64 (1H, bs), 7.08-7.20 (2H, m), 7.28-7.34 (1H, m), 7.37 (2H, d, J = 8.3), 7.72 (2H, d, J = 8.3), 8.24 (1H, s), 9.76 (0.5H, d, J = 5.9), 11.74 (0.5H, s)

Example 82

trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-fluoromethyl)benzenesulfonyl]-cyclohexyl]-amide



Sodium borohydride (0.89 g, 2.3 mmol) was added to a solution of the product from Example 80 (0.40 g, 0.8 mmol) in dry tetrahydrofuran (20 ml) at 0 °C. The mixture was stirred at room temperature for 48 hours, extracted with ethyl acetate (30 ml), the organic layer washed with water (30 ml) and brine (sat. 30 ml), dried (magnesium sulfate) and evaporated *in vacuo* to give crude product (0.43 g). This was chromatographed on silica, eluting with 40% ethyl acetate / isohexane to give the benzyl alcohol (0.25 g, 61%). ¹H NMR (CDCl₃, 360 MHz): 1.67-1.61 (2H, m), 1.94 (1H, t, J = 5.7), 2.02-2.05 (2H, m), 2.43 (2H, bt, J = 13.4), 2.62 (2H, bd, J = 13.6),


3.80 (1H, bs), 4.81 (2H, d, $J = 5.2$), 5.70 (1H, bs), 6.80-6.87 (1H, m), 6.99-7.07 (2H, m), 7.39 (4H, m)

Diethylaminosulfur trifluoride (50 μ l, 0.4 mmol) in dry dichloromethane (1.0 ml) was added to a solution of the aforesaid benzyl alcohol (0.1 g, 0.2 mmol) in dry dichloromethane (1.0 ml) at -78°C . The mixture was allowed to warm to room temperature, stirred for 16 hours, and evaporated *in vacuo*. The crude product was chromatographed on silica, eluting with 20% ethyl acetate / isohexane to give the benzyl fluoride (0.85 g, 83%). ^1H NMR (CDCl_3 , 360 MHz): 1.59-1.68 (2H, m), 2.03-2.06 (2H, m), 2.44 (2H, bt, $J = 13.1$), 2.62 (2H, bd, $J = 12.2$), 3.79-3.82 (1H, m), 5.30 (1H, s), 5.40 (1H, s), 5.63 (1H, d, $J = 8.4$), 6.83 (1H, m), 7.02-7.06 (2H, m), 7.37-7.43 (4H, m)

10

Example 83

15 trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(4-(difluoromethyl)benzenesulfonyl)-cyclohexyl]-amide



Diethylaminosulfur trifluoride (0.10 g, 0.65 mmol) was added to a solution of the product from Example 80 (0.2 g, 0.40 mmol) in dry dichloromethane


20 (2 ml). After stirring for 90 hours at room temperature, the mixture was diluted with water (10 ml). The organic phase was washed with water (10 ml), dried (magnesium sulfate) and evaporated *in vacuo* to give an oil. The crude product was chromatographed on silica, eluting with 20% ethyl acetate / isohexane to give the difluoride (0.17 g, 80%). ^1H NMR (CDCl_3 , 400 MHz): 1.59-1.68 (2H, m), 2.06 (2H, dd, $J = 3.2$ and $J = 14.4$), 2.45 (2H, bt, $J = 13.2$), 2.62 (2H, bd, $J = 14.1$), 3.78-3.83 (1H, m), 5.51 (1H, d, $J =$

25

8.3), 6.69 (1H, t, J = 55.8), 6.79-6.86 (1H, m), 7.04-7.09 (2H, m), 7.49 (2H, d, J = 8.5), 7.55 (2H, d, J = 8.4)

Example 84


- 5 trifluoromethanesulfonic acid, N-[4-(4-cyanobenzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide



Triphenyl phosphine (0.32 g, 1.2 mmol), followed by carbon tetrachloride (0.06 ml, 0.60 mmol), were added to a solution of the product from
10 Example 80 (0.16 g, 0.30 mmol) in acetonitrile (1.5 ml). The mixture was stirred for 1.5 hours, additional carbon tetrachloride (0.18 ml, 0.18 mmol) was added, and the mixture was stirred for 0.5 hours, diluted with water (10 ml) and extracted with diethyl ether (2 x 10 ml). The combined organic phases were washed with brine (sat. 20 ml), dried (magnesium sulfate) and evaporated *in vacuo*. The crude product was chromatographed on silica, eluting with 20% ethyl acetate / isohexane to give the nitrile (0.11 g, 71%). ^1H NMR (CDCl_3 , 360 MHz): 1.63-1.69 (2H, m), 2.04-2.09 (2H, m), 2.48 (2H, bt, J = 13.0), 2.59-2.64 (2H, m), 3.81 (1H, m), 5.66 (1H, d, J = 7.3), 6.79-6.86 (1H, m), 7.07-7.13 (2H, m), 7.52 (2H, d, J = 8.5), 7.70 (2H, d, J = 8.5)

Example 85

- trifluoromethanesulfonic acid, N-[4-(benzenesulfonyl)-4-(2,5-difluorophenyl)-cyclohexyl]-amide



A solution of the product from Example 47 (0.28 g, 0.6 mmol) was flushed with nitrogen, 10% palladium on carbon (0.03 g, 10% w/w) was added, and the mixture was hydrogenated at 40 psi for 16 hours. Filtration and evaporation in vacuo gave the product (0.28 g, 99%). ^1H NMR (CDCl_3 , 400 MHz): 1.61-1.68 (2H, m), 2.03-2.07 (2H, m), 2.44 (2H, bt, $J = 13.2$), 2.63 (2H, bd, $J = 13.5$), 3.78-3.82 (1H, m), 5.64 (1H, d, $J = 8.4$), 6.78-6.85 (1H, m), 6.99-7.08 (2H, m), 7.38-7.43 (4H, m), 7.60-7.65 (1H, m).